By Ethan Jorgensen-Earp (October 31, 2018, 12:43 PM EDT) -- It has been almost impossible to exist in Washington, D.C., during the past several months without encountering the drug pricing debate. From fiery tweets to Rose Garden announcements and speeches, President Donald Trump, along with U.S. Department of Health and Human Services Secretary Alex Azar and other Trump administration officials, have adopted the issue of reduced drug prices as a major domestic policy priority. Masked by this and other discussions about drug development and marketing, however, has been the discussion about the development, approval and reimbursement of medical devices. Recent comments by administration leaders, as well as recent regulatory actions, indicate that the landscape may be changing for the better....